Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation

Journal of Neuroimmunology

Volumn 179, Issue 1-2, 2006, Pages 9-17

  Casnici, C ^a   Lattuada, D ^a   Crotta, K ^a   Mastrotto, C ^a   Franco, P ^a   Culler, M D ^b   Marelli, O ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Biomeasure Inc   (United States)

Author keywords

Dopamine receptors; Human lymphocytes; Receptors dimerization; Somatostatin receptors

Indexed keywords

ALLOANTIGEN; BIM 23023; BIM 23244; BIM 23A757; BIM 23A761; BIM 53057; BIM 53097; BROXURIDINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GAMMA INTERFERON; MITOGENIC AGENT; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2 AGONIST; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVATION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; CELL PROLIFERATION; DOPAMINE AGONISTS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MIDDLE AGED; PEPTIDES, CYCLIC; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; RECOMBINANT FUSION PROTEINS; SOMATOSTATIN;

EID: 33748985148     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.06.025     Document Type: Article

References (31)

1. Agnati L.F., Ferrè S., Lluis C., Franco R., and Fuxe. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev. 55 (2003) 509-550
2. Angers S., Salahpour A., and Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 409-435
3. Basu S., Dasgupta P.S., Lahiri T., and Roychowdhury J. Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice. Life Sci. 53 (1993) 415-424
4. Bergquist J., Tarkowski A., Ekman R., and Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12912-12916
5. Cosentino M., Marino F., Bombelli R., Ferrari M., Lecchini S., and Frigo G. Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils. Life Sci. 64 (1999) 975-981
6. Ferone D., Arvigo M., Semino C., Jaquet P., Saveanu A., Taylor J.E., Moreau J.P., Culler M.D., Albertelli M., Minuto F., and Barreca A. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am. J. Physiol., Endocrinol Metabol. 289 (2005) E1044-E1050
7. 1 dopamine receptor function without affecting receptor oligomerization. J. Biol. Chem. 273 (1998) 30244-30248
8. Ghamrawy C.E., Rabourdin-Combe C., and Krantic S. SST5 somatostatin receptor mRNA induction by mitogenic activation of human T-lymphocytes. Peptides 20 3 (1999) 305-311
9. Grant M., Patel R.C., and Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptor. J. Biol. Chem. 279 (2004) 38636-38643
10. Hornykiewics O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Res. 18 (1966) 925-964
11. 2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. Brain Res. Mol. Brain Res. 47 (1997) 99-107
12. Jaquet P., Gunz G., Saveanu A., Dufour H., Taylor J., Dong J., Kim S., Moreau J.P., Enjalbert A., and Culler M.D. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol. 153 (2005) 135-141
13. Khare S., Kumar U., Sasi R., Puebla L., Calderon L., Lemstrom K., Hayry P., and Patel Y.C. Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty. FASEB J. 13 (1999) 387-394
14. Kumar U., Laird D., Srikant C.B., Escher E., and Patel Y.C. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138 (1997) 4473-4476
15. Kumar U., Sasi R., Suresh S., Patel A., Thangaraju M., Metrakos P., Patel Sc., and Patel Y.C. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48 (1999) 77-85
16. 2 receptors on human T cells, and activates β-integrin function. Eur. J. Immunol. 31 (2001) 3504-3512
17. Martin-Iverson M.T., Radke J.M., and Vincrnt S.R. The effects of cysteamine on dopamine-mediated behaviours: evidence for dopamine-somatostatin interactions in the striatum. Pharmacol. Biochem. Behav. 24 (1986) 1707-1714
18. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., and Moots R.J. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 132 (2002) 34-40
19. Moller L.S., Stidsen C.E., Hartmann B., and Holst J.J. Somatostatin receptors. Biochim. Biophys. Acta 1616 (2003) 1-84
20. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 20 (1999) 157-198
21. Patel Y.C., Panetta R., Escher E., Greenwood M., and Srikant C.B. Expression of multiple somatostatin receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective receptor subtype. J. Biol. Chem. 269 (1994) 1506-1509
22. Patel R.C., Kumar U.M., Lamb D.C., Eid J.S., Rocheville M., Grant M., Rani A., Hazlett T., Patel S.C., Gratton E., and Patel Y.C. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3294-3299
23. Pfeiffer M., Koch T., Schroder H., Klutzny M., Kirscht S., Kreienkamp H.J., Hollt V., and Schulz S. Homo- and heterodimerization of somatostatin receptor subtypes. J. Biol. Chem. 276 (2001) 14027-14036
24. Qui Y., Peng Y., and Wang J. Immunoregulatory role of neurotransmitters. Adv. Neuroimmunol. 6 (1996) 223-231
25. Ren S.G., Kim S., Taylor J., Dong J., Moreau J.P., Culler M.D., and Melmed S. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J. Clin. Endocrinol. Metab. 88 (2003) 5414-5421
26. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., and Patel Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 (2000) 154-157
27. Rocheville M., Lange D.C., Kumar U.M., Sasi R., Patel R.C., and Patel Y.C. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275 (2000) 7862-7869
28. Rodriguez-Sanchez M.N. Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus. J. Neurosci. Res. 48 (1997) 238-248
29. Saveanu A., Lavaque E., Gunz G., Barlier A., Kim S., Taylor J.E., Culler M.D., Enjalbert E., and Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. 87 (2002) 5545-5552
30. ten Bokum A.M., Hofland L., and Van Hagen P. Somatostatin and somatostatin receptors in the immune system: a review. Eur. Cytokine Netw. 11 2 (2000) 161-176
31. Van Hagen P.M., Krenning E.P., Kwekkeboom D.J., and Lamberts S.W. Somatostatin and the immune and haematopoietic system review. Eur. J. Clin. Investig. 24 (1994) 91-99